The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gabrinox: A phase I-II of nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in metastatic pancreatic adenocarcinoma.
 
Eric Assenat
Honoraria - Ipsen; Novartis; Sanofi
Consulting or Advisory Role - Ipsen
Research Funding - Bayer (Inst); Celgene (Inst)
Travel, Accommodations, Expenses - Celgene; Novartis
 
Christelle De La Fouchardiere
Consulting or Advisory Role - Bayer; Celgene
Research Funding - Roche/Genentech
Travel, Accommodations, Expenses - Bayer; Ipsen; Roche
 
Caroline Mollevi
No Relationships to Disclose
 
Emmanuelle Samalin
Honoraria - Amgen; Lilly; Roche; Sanofi
Consulting or Advisory Role - Amgen; Lilly; Roche; Sanofi
Travel, Accommodations, Expenses - Ipsen; Lilly; Novartis; Roche
 
Fabienne Portales
Honoraria - Sanofi
Consulting or Advisory Role - Sanofi
Research Funding - Celgene (Inst)
Travel, Accommodations, Expenses - Ipsen
 
Françoise Desseigne
No Relationships to Disclose
 
Christophe Carenco
No Relationships to Disclose
 
Marie Dupuy
No Relationships to Disclose
 
Ernesto Lopez-Martinez
No Relationships to Disclose
 
Catherine Fiess
No Relationships to Disclose
 
Thibault Mazard
Honoraria - Amgen; Sanofi
Research Funding - Roche Pharma AG (Inst)
Travel, Accommodations, Expenses - Amgen
 
Marc Ychou
Honoraria - Bayer; Celgene; Merck Serono; Roche/Genentech
Consulting or Advisory Role - Bayer; Celgene; Roche